Interleukin-19
AssigneeHuman Genome Sciences, Inc.
InventorsCraig Rosen, Joseph Kenny
Life of this patent
Estimating the term…
Abstract
The present invention concerns a novel human cytokine. In particular, isolated nucleic acid molecules are provided encoding interleukin-19 (IL-19). IL-19 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The IL-19 polypeptides of the present invention can also be used to raise polyclonal and monoclonal antibodies. The invention further concerns therapeutic methods for modulating cytokine production.
Claims18
An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about −24 to about 153 in SEQ ID NO:2;
- (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about −23 to about 153 in SEQ ID NO:2;
- (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 153 in SEQ ID NO:2;
- (d) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97662;
- (e) a nucleotide sequence encoding the mature IL-19 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97662;
- and
- (f) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d) or (e).
An isolated nucleic acid molecule, comprising a polynucleotide having a sequence selected from the group consisting of the nucleotide sequence of a fragment of the sequence shown in SEQ ID NO:
- 1 or the complement thereof, wherein said fragment comprises at least 50 contiguous nucleotides of SEQ ID NO:
- 1, provided that said fragment does not have a sequence starting:
- (a) at nucleotide 9 and ending at nucleotide 302 of SEQ ID NO:1 or any subfragment thereof or the complement thereof;
- or
- (b) at nucleotide 438 and ending at nucleotide 934 of SEQ ID NO:1 or any subfragment thereof or the complement thereof.
An isolated IL-19 polypeptide having an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:
- (a) amino acids from about −24 to about 153 in SEQ ID NO:2;
- (b) amino acids from about −23 to about 153 in SEQ ID NO:2;
- (c) amino acids from about 1 to about 153 in SEQ ID NO:2;
- (d) the amino acid sequence of the IL-19 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97662;
- (e) the amino acid sequence of the mature IL-19 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97662;
- and
- (f) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d) or (e).
An isolated polypeptide comprising an epitope-bearing portion of the IL-19 protein, wherein said portion is selected from the group consisting of:
- a polypeptide comprising amino acid residues from about −5 to about 4 in SEQ ID NO:2;
- a polypeptide comprising amino acid residues from about 64 to about 82 in SEQ ID NO:2;
- and a polypeptide comprising amino acid residues from about 115 to about 125 in SEQ ID NO:2.
An isolated nucleic acid molecule comprising a polynucleotide encoding an IL-19 polypeptide wherein, except for at least one to fifty conservative amino acid substitution, said polypeptide has a sequence selected from the group consisting of:
- (a) a nucleotide sequence encoding a polypeptide comprising amino acids from about −24 to about 153 in SEQ ID NO:2;
- (b) a nucleotide sequence encoding a polypeptide comprising amino acids from about −23 to about 153 in SEQ ID NO:2;
- (c) a nucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 153 in SEQ ID NO:2;
- (d) a nucleotide sequence encoding a polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97662;
- (e) a nucleotide sequence encoding the mature IL-19 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97662;
- and
- (f) a nucleotide sequence complementary to any of the nucleotide sequences in (a), (b), (c), (d) or (e).
An isolated IL-19 polypeptide wherein, except for at least one to fifty conservative amino acid substitution, said polypeptide has a sequence selected from the group consisting of:
- (a) amino acids from about −24 to about 153 in SEQ ID NO:2;
- (b) amino acids from about −23 to about 153 in SEQ ID NO:2;
- (c) amino acids from about 1 to about 153 in SEQ ID NO:2;
- (d) the amino acid sequence of the IL-19 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97662;
- (e) the amino acid sequence of the mature IL-19 polypeptide having the amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 97662;
- and
- (f) the amino acid sequence of an epitope-bearing portion of any one of the polypeptides of (a), (b), (c), (d) or (e).
A method for treatment of an individual in need of an increase in IL-2 activity, comprising administering to said individual a composition comprising an antagonist of interleukin-19 activity.
Dependencies are inferred from the claim text.